SkinBioTherapeutics (LSE:SBTX) Ending Cash Position : £2.84 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is SkinBioTherapeutics Ending Cash Position?

SkinBioTherapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was £2.84 Mil.

SkinBioTherapeutics's quarterly Ending Cash Position increased from Dec. 2022 (£0.77 Mil) to Jun. 2023 (£1.31 Mil) and increased from Jun. 2023 (£1.31 Mil) to Dec. 2023 (£2.84 Mil).

SkinBioTherapeutics's annual Ending Cash Position declined from Jun. 2021 (£4.61 Mil) to Jun. 2022 (£1.81 Mil) and declined from Jun. 2022 (£1.81 Mil) to Jun. 2023 (£1.31 Mil).

SkinBioTherapeutics Ending Cash Position Historical Data

The historical data trend for SkinBioTherapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SkinBioTherapeutics Ending Cash Position Chart

SkinBioTherapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Ending Cash Position

Get a 7-Day Free Trial

3.13

2.16

4.61

1.81

1.31

SkinBioTherapeutics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial										3.15	1.81	0.77	1.31	2.84

SkinBioTherapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SkinBioTherapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1.805	+	-0.493
	=	1.31

SkinBioTherapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1.311	+	1.53
	=	2.84

SkinBioTherapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of SkinBioTherapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

SkinBioTherapeutics (LSE:SBTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SkinBioTherapeutics PLC (LSE:SBTX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bath Lane, The Core, Newcastle Helix, Newcastle upon Tyne, GBR, NE4 5TF

Website

https://www.skinbiotherapeutics.com

SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.